# Peter J Halfmann

List of Publications by Year
in descending order



| 76 | 10,805 | 109321 35 | 76900 74 |
|---|---|---|---|
| papers | citations | h-index | g-index |

| 94 | 94 | 94 | 14467 |
|---|---|---|---|
| all docs | docs citations | times ranked | citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Molecular Basis for High Virulence of Hong Kong H5N1 Influenza A Viruses. Science, 2001, 293, 1840-1842. | 12.6 | 1,218 |
| 2 | Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift. Nature, 2022, 602, 664-670. | 27.8 | 917 |
| 3 | Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 16587-16595. | 7.1 | 912 |
| 4 | Aberrant innate immune response in lethal infection of macaques with the 1918 influenza virus. Nature, 2007, 445, 319-323. | 27.8 | 892 |
| 5 | SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and transmission in vivo. Science, 2020, 370, 1464-1468. | 12.6 | 808 |
| 6 | An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies. Nature Medicine, 2022, 28, 490-495. | 30.7 | 577 |
| 7 | SARS-CoV-2 Omicron virus causes attenuated disease in mice and hamsters. Nature, 2022, 603, 687-692. | 27.8 | 475 |
| 8 | Enhanced virulence of influenza A viruses with the haemagglutinin of the 1918 pandemic virus. Nature, 2004, 431, 703-707. | 27.8 | 434 |
| 9 | Transmission of SARS-CoV-2 in Domestic Cats. New England Journal of Medicine, 2020, 383, 592-594. | 27.0 | 430 |
| 10 | Ebolavirus Is Internalized into Host Cells via Macropinocytosis in a Viral Glycoprotein-Dependent Manner. PLoS Pathogens, 2010, 6, e1001121. | 4.7 | 366 |
| 11 | Structural Rearrangement of Ebola Virus VP40 Begets Multiple Functions in the Virus Life Cycle. Cell, 2013, 154, 763-774. | 28.9 | 201 |
| 12 | A Role for Fc Function in Therapeutic Monoclonal Antibody-Mediated Protection against Ebola Virus. Cell Host and Microbe, 2018, 24, 221-233.e5. | 11.0 | 182 |
| 13 | Characterization and antiviral susceptibility of SARS-CoV-2 Omicron BA.2. Nature, 2022, 607, 119-127. | 27.8 | 174 |
| 14 | Longitudinal Analysis of the Human B Cell Response to Ebola Virus Infection. Cell, 2019, 177, 1566-1582.e17. | 28.9 | 153 |
| 15 | The Synthetic Antiviral Drug Arbidol Inhibits Globally Prevalent Pathogenic Viruses. Journal of Virology, 2016, 90, 3086-3092. | 3.4 | 133 |
| 16 | The spatio-temporal distribution dynamics of Ebola virus proteins and RNA in infected cells. Scientific Reports, 2013, 3, 1206. | 3.3 | 123 |
| 17 | Defining the risk of SARS-CoV-2 variants on immune protection. Nature, 2022, 605, 640-652. | 27.8 | 117 |
| 18 | Generation of biologically contained Ebola viruses. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 1129-1133. | 7.1 | 113 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | A shared structural solution for neutralizing ebolaviruses. Nature Structural and Molecular Biology, 2011, 18, 1424-1427. | 8.2 | 113 |
| 20 | Profiling B cell immunodominance after SARS-CoV-2 infection reveals antibody evolution to non-neutralizing viral targets. Immunity, 2021, 54, 1290-1303.e7. | 14.3 | 101 |
| 21 | Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift. Nature, 0, , . | 27.8 | 101 |
| 22 | Resilience of S309 and AZD7442 monoclonal antibody treatments against infection by SARS-CoV-2 Omicron lineage strains. Nature Communications, 2022, 13, . | 12.8 | 93 |
| 23 | Identification of mammalian-adapting mutations in the polymerase complex of an avian H5N1 influenza virus. Nature Communications, 2015, 6, 7491. | 12.8 | 91 |
| 24 | Characterization of a Human H5N1 Influenza A Virus Isolated in 2003. Journal of Virology, 2005, 79, 9926-9932. | 3.4 | 90 |
| 25 | Transmission of SARS-CoV-2 in domestic cats imposes a narrow bottleneck. PLoS Pathogens, 2021, 17, e1009373. | 4.7 | 84 |
| 26 | The Cytoprotective Enzyme Heme Oxygenase-1 Suppresses Ebola Virus Replication. Journal of Virology, 2013, 87, 13795-13802. | 3.4 | 81 |
| 27 | An Ebola whole-virus vaccine is protective in nonhuman primates. Science, 2015, 348, 439-442. | 12.6 | 81 |
| 28 | SARS-CoV-2 Infection Severity Is Linked to Superior Humoral Immunity against the Spike. MBio, 2021, 12, . | 4.1 | 81 |
| 29 | Replication-Deficient Ebolavirus as a Vaccine Candidate. Journal of Virology, 2009, 83, 3810-3815. | 3.4 | 73 |
| 30 | Novel residues in avian influenza virus PB2 protein affect virulence in mammalian hosts. Nature Communications, 2014, 5, 5021. | 12.8 | 73 |
| 31 | Characterization of a new SARS-CoV-2 variant that emerged in Brazil. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, . | 7.1 | 63 |
| 32 | Plasma lipidome reveals critical illness and recovery from human Ebola virus disease. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 3919-3928. | 7.1 | 62 |
| 33 | The landscape of antibody binding in SARS-CoV-2 infection. PLoS Biology, 2021, 19, e3001265. | 5.6 | 58 |
| 34 | Antibody-Dependent Enhancement of SARS-CoV-2 Infection Is Mediated by the IgG Receptors FcÎ³RIIA and FcÎ³RIIIA but Does Not Contribute to Aberrant Cytokine Production by Macrophages. MBio, 2021, 12, e0198721. | 4.1 | 57 |
| 35 | Structure of an Antibody in Complex with Its Mucin Domain Linear Epitope That Is Protective against Ebola Virus. Journal of Virology, 2012, 86, 2809-2816. | 3.4 | 46 |
| 36 | MPLEx: a method for simultaneous pathogen inactivation and extraction of samples for multi-omics profiling. Analyst, The, 2017, 142, 442-448. | 3.5 | 43 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | The Ebolavirus VP24 Protein Blocks Phosphorylation of p38 Mitogen-Activated Protein Kinase. Journal of Infectious Diseases, 2011, 204, S953-S956. | 4.0 | 40 |
| 38 | Revealing fine-scale spatiotemporal differences in SARS-CoV-2 introduction and spread. Nature Communications, 2020, 11, 5558. | 12.8 | 39 |
| 39 | Hypergraph models of biological networks to identify genes critical to pathogenic viral response. BMC Bioinformatics, 2021, 22, 287. | 2.6 | 39 |
| 40 | Nasally delivered interferon-Î» protects mice against infection by SARS-CoV-2 variants including Omicron. Cell Reports, 2022, 39, 110799. | 6.4 | 39 |
| 41 | Identification of interferon-stimulated genes that attenuate Ebola virus infection. Nature Communications, 2020, 11, 2953. | 12.8 | 37 |
| 42 | Mutations in the PA Protein of Avian H5N1 Influenza Viruses Affect Polymerase Activity and Mouse Virulence. Journal of Virology, 2018, 92, . | 3.4 | 36 |
| 43 | Multivalent nanoparticle-based vaccines protect hamsters against SARS-CoV-2 after a single immunization. Communications Biology, 2021, 4, 597. | 4.4 | 35 |
| 44 | Suppressor of Cytokine Signaling 3 Is an Inducible Host Factor That Regulates Virus Egress during Ebola Virus Infection. Journal of Virology, 2015, 89, 10399-10406. | 3.4 | 34 |
| 45 | A Fc engineering approach to define functional humoral correlates of immunity against Ebola virus. Immunity, 2021, 54, 815-828.e5. | 14.3 | 34 |
| 46 | Crystal Structure of Marburg Virus VP40 Reveals a Broad, Basic Patch for Matrix Assembly and a Requirement of the N-Terminal Domain for Immunosuppression. Journal of Virology, 2016, 90, 1839-1848. | 3.4 | 33 |
| 47 | Durability of immune responses to the BNT162b2 mRNA vaccine. Med, 2022, 3, 25-27. | 4.4 | 33 |
| 48 | DNA Topoisomerase 1 Facilitates the Transcription and Replication of the Ebola Virus Genome. Journal of Virology, 2013, 87, 8862-8869. | 3.4 | 29 |
| 49 | Highly Efficient SARS-CoV-2 Infection of Human Cardiomyocytes: Spike Protein-Mediated Cell Fusion and Its Inhibition. Journal of Virology, 2021, 95, e0136821. | 3.4 | 29 |
| 50 | SARS-CoV-2 Interference of Influenza Virus Replication in Syrian Hamsters. Journal of Infectious Diseases, 2022, 225, 282-286. | 4.0 | 25 |
| 51 | Cross-Neutralization of Emerging SARS-CoV-2 Variants of Concern by Antibodies Targeting Distinct Epitopes on Spike. MBio, 2021, 12, e0297521. | 4.1 | 24 |
| 52 | Protective Immunity and Persistent Lung Sequelae in Domestic Cats after SARS-CoV-2 Infection. Emerging Infectious Diseases, 2021, 27, 660-663. | 4.3 | 23 |
| 53 | Specific COVID-19 Symptoms Correlate with High Antibody Levels against SARS-CoV-2. ImmunoHorizons, 2021, 5, 466-476. | 1.8 | 23 |
| 54 | The Induction of IL-1Î² Secretion Through the NLRP3 Inflammasome During Ebola Virus Infection. Journal of Infectious Diseases, 2018, 218, S504-S507. | 4.0 | 22 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Characterization of the SARS-CoV-2 B.1.621 (Mu) variant. Science Translational Medicine, 2022, 14, eabm4908. | 12.4 | 21 |
| 56 | Potent neutralization of <scp>SARSâ€CoV</scp>â€2 including variants of concern by vaccines presenting the receptorâ€binding domain multivalently from nanoscaffolds. Bioengineering and Translational Medicine, 2021, 6, e10253. | 7.1 | 19 |
| 57 | Loss of Interleukin 1 Receptor Antagonist Enhances Susceptibility to Ebola Virus Infection. Journal of Infectious Diseases, 2015, 212, S329-S335. | 4.0 | 18 |
| 58 | HER2-mediated enhancement of Ebola virus entry. PLoS Pathogens, 2020, 16, e1008900. | 4.7 | 17 |
| 59 | Co-administration of Favipiravir and the Remdesivir Metabolite GS-441524 Effectively Reduces SARS-CoV-2 Replication in the Lungs of the Syrian Hamster Model. MBio, 2022, 13, e0304421. | 4.1 | 17 |
| 60 | Early Human B Cell Response to Ebola Virus in Four U.S. Survivors of Infection. Journal of Virology, 2019, 93, . | 3.4 | 15 |
| 61 | Ambient Temperature Stable, Scalable COVIDâ€19 Polymer Particle Vaccines Induce Protective Immunity. Advanced Healthcare Materials, 2022, 11, e2102089. | 7.6 | 14 |
| 62 | Efficacy of vaccination and previous infection against the Omicron BA.1 variant in Syrian hamsters. Cell Reports, 2022, 39, 110688. | 6.4 | 14 |
| 63 | Ebola Virus Stability Under Hospital and Environmental Conditions. Journal of Infectious Diseases, 2016, 214, S142-S144. | 4.0 | 13 |
| 64 | Serological analysis of Ebola virus survivors and close contacts in Sierra Leone: A cross-sectional study. PLoS Neglected Tropical Diseases, 2019, 13, e0007654. | 3.0 | 12 |
| 65 | Novel modulators of p53-signaling encoded by unknown genes of emerging viruses. PLoS Pathogens, 2021, 17, e1009033. | 4.7 | 12 |
| 66 | Long-term, infection-acquired immunity against the SARS-CoV-2 Delta variant in a hamster model. Cell Reports, 2022, 38, 110394. | 6.4 | 9 |
| 67 | Comparative Sensitivity of Rapid Antigen Tests for the Delta Variant (B.1.617.2) of SARS-CoV-2. Viruses, 2021, 13, 2183. | 3.3 | 8 |
| 68 | mRNA-1273 and Ad26.COV2.S vaccines protect against the B.1.621 variant of SARS-CoV-2. Med, 2022, 3, 309-324.e6. | 4.4 | 6 |
| 69 | Pseudoparticle Neutralization Assay for Detecting Ebola- Neutralizing Antibodies in Biosafety Level 2 Settings. Clinical Chemistry, 2015, 61, 885-886. | 3.2 | 5 |
| 70 | Isolation of Highly Pathogenic H5N1 Influenza Viruses in 2009â€“2013 in Vietnam. Frontiers in Microbiology, 2019, 10, 1411. | 3.5 | 5 |
| 71 | Formulation and production of a bloodâ€free and chemically defined virus production media for VERO cells. Biotechnology and Bioengineering, 2020, 117, 3277-3285. | 3.3 | 3 |
| 72 | Repurposing Fragile X Drugs to Inhibit SARS-CoV-2 Viral Reproduction. Frontiers in Cell and Developmental Biology, 2020, 8, 856. | 3.7 | 2 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | Mediator complex subunit 12 is a gatekeeper of SARS-CoV-2 infection in breast cancer cells. Genes and Diseases, 2022, 9, 5-8. | 3.4 | 2 |
| 74 | A Novel Method to Reduce ELISA Serial Dilution Assay Workload Applied to SARS-CoV-2 and Seasonal HCoVs. Viruses, 2022, 14, 562. | 3.3 | 2 |
| 75 | Ebola Conquers West Africa â€" More to Come?. EBioMedicine, 2014, 1, 2-3. | 6.1 | 1 |
| 76 | Genetic incompatibility among influenza A viruses. International Congress Series, 2001, 1219, 1019-1021. | 0.2 | 0 |